Tyligand Bioscience

Shanghai, China · Founded 2018 · In IPO Registration

Developer and manufacturer of oral oncology drugs and antibody-drug conjugate platforms designed for KRAS-mutated and other solid tumors. Tyligand Bioscience is based in Shanghai, China and was founded in 2018. Its last reported valuation was $222 million in Jan 2026. It has raised $111 million.

Last reported valuation
$222.2M
Oct 2026
Priced at
—
Total raised
$110.6M
Last round
—
What is Tyligand Bioscience worth?
$222.2Mlast reported valuation · Oct 2026

Tyligand Bioscience's last reported valuation, Jan 2026. Nothing priced has surfaced since.

Free account
More of Tyligand Bioscience with a free account
  • ·The complete investor list: 14 names
  • ·Watch Tyligand Bioscience: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Tyligand Bioscience funding history

No rounds on record

No funding rounds for Tyligand Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Tyligand Bioscience valuation

Tyligand Bioscience's last reported valuation was $222 million in Jan 2026. No priced round, secondary trade or fund mark has surfaced since.

How Tyligand Bioscience's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Tyligand Bioscience, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →

Frequently asked about Tyligand Bioscience

What is Tyligand Bioscience worth?
Tyligand Bioscience is valued at $222.2M as of Oct 2026. Tyligand Bioscience's last reported valuation, Jan 2026. Nothing priced has surfaced since.
How much has Tyligand Bioscience raised?
Tyligand Bioscience has raised $110.6M in total funding across its recorded rounds.